NCT00162955View on ClinicalTrials.gov

Prevention of CHOP-induced Chronic Cardiotoxicity

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Valsartan

Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.

Trial Locations (1)

545-8585

Graduate School of Medicine, Osaka City University, Osaka

All Listed Sponsors
lead

Osaka City University

OTHER

NCT00162955 - Prevention of CHOP-induced Chronic Cardiotoxicity | Biotech Hunter | Biotech Hunter